Display options
Cite
Mirian C, Grell K, Juratli TA, et al. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathol Appl Neurobiol. 2021;doi: 10.1111/nan.12773.
Mirian, C., Grell, K., Juratli, T. A., Sahm, F., Spiegl-Kreinecker, S., Peyre, M., Biczok, A., Tonn, J. C., Goutagny, S., Bertero, L., Maier, A. D., Jensen, L. R., Schackert, G., Broholm, H., Scheie, D., Cahill, D. P., Brastianos, P. K., Skjøth-Rasmussen, J., Fugleholm, K., Ziebell, M., Munch, T. N., Kristensen, B. W., & Mathiesen, T. (2021). Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathology and applied neurobiology, . https://doi.org/10.1111/nan.12773
Mirian, Christian, et al. "Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma." Neuropathology and applied neurobiology vol. (2021). doi: https://doi.org/10.1111/nan.12773
Mirian C, Grell K, Juratli TA, Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny S, Bertero L, Maier AD, Jensen LR, Schackert G, Broholm H, Scheie D, Cahill DP, Brastianos PK, Skjøth-Rasmussen J, Fugleholm K, Ziebell M, Munch TN, Kristensen BW, Mathiesen T. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathol Appl Neurobiol. 2021 Nov 19; doi: 10.1111/nan.12773. Epub 2021 Nov 19. PMID: 34799864.
Copy Download .nbib Format: NLM
Share it on

Neuropathol Appl Neurobiol. 2021 Nov 19; doi: 10.1111/nan.12773. Epub 2021 Nov 19.

Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma.

Neuropathology and applied neurobiology

Christian Mirian, Kathrine Grell, Tareq A Juratli, Felix Sahm, Sabine Spiegl-Kreinecker, Matthieu Peyre, Annamaria Biczok, Jörg-Christian Tonn, Stéphane Goutagny, Luca Bertero, Andrea Daniela Maier, Lasse Rehné Jensen, Gabriele Schackert, Helle Broholm, David Scheie, Daniel P Cahill, Priscilla K Brastianos, Jane Skjøth-Rasmussen, Kåre Fugleholm, Morten Ziebell, Tina Nørgaard Munch, Bjarne Winther Kristensen, Tiit Mathiesen

Affiliations

  1. Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  2. Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  3. Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  4. Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  5. Department of Neurosurgery, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  6. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  7. Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  8. Department of Neurosurgery, Kepler University Hospital GmbH, Johannes Kepler University, Linz, Austria.
  9. Sorbonne Universités, Department of Neurosurgery, Groupe Hospitalier Pitié-Salpêtrière, APHP, F-75013, Paris, France.
  10. Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany.
  11. Department of Neurosurgery, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Université de Paris, Paris, France.
  12. Pathology Unit, Department of Medical Sciences, University of Turin, Torino, Italy.
  13. Department of Pathology, Center of Diagnostic Investigation, Copenhagen University Hospital, Copenhagen, Denmark.
  14. Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  15. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  16. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  17. Department of Clinical Neuroscience, Karolinska Institute, Solna, Sweden.

PMID: 34799864 DOI: 10.1111/nan.12773

Abstract

TERT promoter mutations have been associated with increased risk of recurrence in meningioma cohorts, thus a potential biomarker for aggressive phenotypes. A main purpose of refining tumour classification is better predictions on the patient level. We compiled data from previous published cohorts to investigate patient-level predictions of recurrence based on TERTp-mut status. Implementation of TERTp-mut into the WHO grading led to better patient prognostication by improved prediction of recurrence. Our results support implementation of TERTp-mut into diagnostics and classification of meningiomas.

© 2021 British Neuropathological Society.

References

  1. Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682-694. https://doi.org/10.1016/S1470-2045(17)30155-9 - PubMed
  2. Sievers P, Hielscher T, Schrimpf D, et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 2020;140(3):409-413. https://doi.org/10.1007/s00401-020-02188-w - PubMed
  3. Mirian C, Duun-Henriksen AK, Juratli T, et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91(4):378-387. https://doi.org/10.1136/jnnp-2019-322257 - PubMed
  4. Williams EA, Santagata S, Wakimoto H, et al. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020;8(1):171. https://doi.org/10.1186/s40478-020-01040-2 - PubMed
  5. Juratli TA, McCabe D, Nayyar N, et al. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136(5):779-792. https://doi.org/10.1007/s00401-018-1899-7 - PubMed
  6. Juratli TA, Brastianos PK, Cahill DP. TERT alterations in progressive treatment-resistant meningiomas. Neurosurgery. 2018;65(CN_suppl_1):66-68. https://doi.org/10.1093/neuros/nyy154 - PubMed
  7. Juratli TA, Thiede C, Koerner MVA, et al. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017;8(65):109228-109237. https://doi.org/10.18632/oncotarget.22650 - PubMed
  8. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24(2):184-189. https://doi.org/10.1111/bpa.12110 - PubMed
  9. Peyre M, Gauchotte G, Giry M, et al. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. Neuro Oncol. 2018;20(8):1113-1121. https://doi.org/10.1093/neuonc/nox231 - PubMed
  10. Biczok A, Kraus T, Suchorska B, et al. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. J Neurooncol. 2018;139(3):671-678. https://doi.org/10.1007/s11060-018-2912-7 - PubMed
  11. Spiegl-Kreinecker S, Lotsch D, Neumayer K, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 2018;20(12):1584-1593. https://doi.org/10.1093/neuonc/noy104 - PubMed
  12. Bertero L, Dalla Dea G, Osella-Abate S, et al. Prognostic characterization of higher-grade meningiomas: a histopathological score to predict progression and outcome. J Neuropathol Exp Neurol. 2019;78(3):248-256. https://doi.org/10.1093/jnen/nly127 - PubMed
  13. Maier AD, Stenman A, Svahn F, et al. TERT promoter mutations in primary and secondary WHO grade III meningioma. Brain Pathol. 2020;31(1):61-69. https://doi.org/10.1111/bpa.12892 - PubMed
  14. Sahm F, Schrimpf D, Olar A, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108(5):djv377. https://doi.org/10.1093/jnci/djv377 - PubMed
  15. Biczok A, Jungk C, Egensperger R, et al. Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome. J Neurooncol. 2019;145(3):469-477. https://doi.org/10.1007/s11060-019-03312-x - PubMed

Publication Types